Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Homologous recombination deficiency (HRD) can predict the therapeutic outcomes of immuno-neoadjuvant therapy in NSCLC patients

18 May 2022

Abstract excerpt

BACKGROUND: Neoadjuvant immunotherapy is emerging as novel effective intervention in lung cancer, but study to unearth effective surrogates indicating its therapeutic outcomes is limited. We investigated the genetic changes between non-small cell lung cancer (NSCLC) patients with varied response to neoadjuvant immunotherapy and discovered highly potential biomarkers with indicative capability in predicting...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to DNA Repair Mechanisms
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35585646
DOI: 10.1186/s13045-022-01283-7

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Homologous recombination deficiency (HRD) can predict the therapeutic outcomes of immuno-neoadjuvant therapy in NSCLC patientsPMID 35585646Read ↗

Homologous recombination deficiency (HRD) can predict the therapeutic outcomes of immuno-neoadjuvant therapy in NSCLC patientsSemantic proximity Read ↗

Clinical and molecular significance of homologous recombination deficiency positive non-small cell lung cancer in Chinese population: An integrated genomic and transcriptional analysisSemantic proximity Read ↗

Efficacy of immunotherapy in lung cancer with co-occurring mutations in NOTCH and homologous repair genes.Semantic proximity Read ↗

A subset of lung cancer cases shows robust signs of homologous recombination deficiency associated genomic mutational signaturesSemantic proximity Read ↗

DNA Damage Response and Repair Gene Alterations Increase Tumor Mutational Burden and Promote Poor Prognosis of Advanced Lung CancerSemantic proximity Read ↗

A subset of lung cancer cases shows robust signs of homologous recombination deficiency associated genomic mutational signaturesSemantic proximity Read ↗

Pan-cancer analysis reveals homologous recombination deficiency score as a predictive marker for immunotherapy responders.Semantic proximity Read ↗

Somatic mutations in homologous recombination pathway predict favorable prognosis after immunotherapy across multiple cancer typesSemantic proximity Read ↗

Multiomics analysis of homologous recombination deficiency across cancer types.Semantic proximity Read ↗

Molecular architecture of the tumor microenvironment caused by <i>BRCA1</i> and <i>BRCA2</i> somatic mutations in lung adenocarcinomaSemantic proximity Read ↗

Genomic characterization of DNA damage response pathway mutations reveals their adverse impact on EGFR-TKI efficacy in non-small cell lung cancer.Semantic proximity Read ↗

Homologous recombination deficiency (HRD) is associated with better prognosis and possibly causes a non-inflamed tumour microenvironment in nasopharyngeal carcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.